Infant Bacterial Therapeutics AB (publ)

OM:IBT B Stock Report

Market Cap: kr1.2b

Infant Bacterial Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Infant Bacterial Therapeutics has a total shareholder equity of SEK305.2M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK351.3M and SEK46.2M respectively.

Key information

0%

Debt to equity ratio

kr0

Debt

Interest coverage ration/a
Cashkr329.06m
Equitykr305.15m
Total liabilitieskr46.18m
Total assetskr351.33m

Recent financial health updates

Recent updates

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03
Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16
Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25
We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06
We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07
Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Financial Position Analysis

Short Term Liabilities: IBT B's short term assets (SEK341.6M) exceed its short term liabilities (SEK46.2M).

Long Term Liabilities: IBT B has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: IBT B is debt free.

Reducing Debt: IBT B has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBT B has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IBT B has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 17.4% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.